Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine and Dextromethorphan in OCD and Related Disorders
NCT04899687Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Jan 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dextromethorphan in obsessive compulsive disorder (OCD), illness anxiety disorder (IAD), body dysmorphic disorder (BDD), somatic symptom disorder (SSD), sponsored by Stanford University. Started Jan 2022; status: recruiting.
02
Drugs
dextromethorphan
03
Conditions
obsessive compulsive disorder (OCD)illness anxiety disorder (IAD)body dysmorphic disorder (BDD)somatic symptom disorder (SSD)
Beyond the preview
Go deeper on NCT04899687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899687.